Skip to main content
Midas Edge

Acurx Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

ACXP$1.060.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Shareholders’ Equity

​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​​​​​​​​Additional​​​​​Total
​​ ​ ​​​ ​ ​​ ​ ​​​ ​ ​​ ​ ​Paid-In​ ​ ​​ ​ ​Accumulated​ ​ ​​ ​ ​Shareholders’
​​Shares​​Amount​​Capital​​Deficit​​Equity
Balance at January 1, 2024723,411$723$57,884,815$(53,218,853)$4,666,685
Share-Based Compensation​—​​—​​2,601,903​—​2,601,903
Share-Based Payments to Vendors​17,659​​18​​833,662​—​833,680
Issuance of shares of common stock in At-the-Market sales agreement, net of $209,305 cash issuance costs​107,504​​108​​6,405,649​—​6,405,757
Warrant Exercise​2,960​​3​​210,196​​—​​210,199
Net Loss—​—​—​(14,103,103)​(14,103,103)
Balance at December 31, 2024851,534$852$67,936,225$(67,321,956)$615,121
Reverse Stock Split fractional share adjustment​(167)​​—​​(1,040)​​—​​(1,040)
Share-Based Compensation​—​​—​​1,247,401​​—​​1,247,401
Share-Based Compensation to settle accrued compensation​—​​—​​413,120​​—​​413,120
Share-Based Payments to Vendors​47,643​​48​​322,271​​—​​322,319
Issuance of shares of common stock in January Registered Direct Offering, net of $400,750 cash issuance costs​123,153​​123​​2,099,130​​—​​2,099,253
Issuance of shares of common stock and pre-funded warrants in March Registered Direct Offering, net of $208,580 cash issuance costs​107,500​​107​​889,313​​—​​889,420
Pre-funded Warrant Exercise​29,750​​30​​(30)​​—​​—
Issuance of shares of common stock related to equity line of credit purchase agreement, net of $144,991 cash issuance costs​796,360​​796​​3,807,643​​—​​3,808,439
Issuance of shares of common stock related to warrant inducement, net of $186,708 cash issuance costs​222,272​​222​​2,480,331​​—​​2,480,553
Warrant Exercise​170,068​​170​​1,360,374​​—​​1,360,544
Net Loss—​—​—​(7,966,538)​(7,966,538)
Balance at December 31, 20252,348,113​$2,348​$80,554,738​$(75,288,494)​$5,268,592
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.